STADA Arzneimittel (ETR:SAZ) has been assigned a €89.00 ($109.88) price objective by research analysts at Independent Research in a report released on Monday. The firm currently has a “neutral” rating on the stock. Independent Research’s target price would indicate a potential upside of 3.22% from the company’s previous close.
A number of other equities analysts have also recently issued reports on the stock. Nord/LB set a €74.40 ($91.85) target price on shares of STADA Arzneimittel and gave the stock a “sell” rating in a research report on Wednesday, November 29th. Commerzbank set a €66.25 ($81.79) price target on shares of STADA Arzneimittel and gave the stock a “sell” rating in a report on Tuesday, December 26th. Finally, Warburg Research set a €74.40 ($91.85) price target on shares of STADA Arzneimittel and gave the stock a “sell” rating in a report on Wednesday, December 20th. Five research analysts have rated the stock with a sell rating and two have issued a hold rating to the company. STADA Arzneimittel currently has an average rating of “Sell” and a consensus target price of €73.49 ($90.73).
Shares of STADA Arzneimittel (SAZ) remained flat at $€86.22 ($106.44) on Monday. The stock had a trading volume of 37,347 shares, compared to its average volume of 51,923. The company has a market cap of $5,370.00 and a price-to-earnings ratio of 62.93. STADA Arzneimittel has a fifty-two week low of €53.41 ($65.94) and a fifty-two week high of €90.24 ($111.41).
About STADA Arzneimittel
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.